Knocking off cancer's HAT: CSS1477 disrupts oncogenic programs

Luyao Kevin Xu; Panagiotis Ntziachristos

doi:10.1016/j.chembiol.2023.11.014

Knocking off cancer's HAT: CSS1477 disrupts oncogenic programs

Cell Chem Biol. 2023 Dec 21;30(12):1505-1507. doi: 10.1016/j.chembiol.2023.11.014.

Authors

Luyao Kevin Xu¹, Panagiotis Ntziachristos²

Affiliations

¹ Department of Biomolecular Medicine, Ghent University, Ghent, Belgium; Center for Medical Genetics, Ghent University and University Hospital, Ghent, Belgium; Bioscience, Oncology R&D, AstraZeneca, Waltham, MA, USA.
² Department of Biomolecular Medicine, Ghent University, Ghent, Belgium; Center for Medical Genetics, Ghent University and University Hospital, Ghent, Belgium; Cancer Research Institute Ghent (CRIG), Ghent, Belgium. Electronic address: [email protected].

PMID: 38134880
DOI: 10.1016/j.chembiol.2023.11.014

Abstract

EP300/CBP are histone acetyltransferases recruited onto chromatin by oncogenic transcription factors and control the transcriptional program via their activity in enhancer areas. In the December issue of Cancer Cell, Nicosia et al.¹ offer new promise in targeting EP300/CBP using the small-molecule inhibitor CSS1477 in patients with blood tumors and no other therapeutic options.

Publication types

Comment

MeSH terms

CREB-Binding Protein*
Chromatin
Histone Acetyltransferases
Humans
Neoplasms* / genetics
Transcription Factors

Substances

CREB-Binding Protein
Transcription Factors
Histone Acetyltransferases
Chromatin